Amneal Pharmaceuticals Inc [AMRX] stock is trading at $6.02, up 3.61%. An important factor to consider is whether the stock is rising or falling in short-term value. The AMRX shares have gain 2.91% over the last week, with a monthly amount glided 11.48%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, March 2024, Amneal to Ring the Nasdaq Closing Bell on April 2, 2024. In a post published today on Yahoo Finance, – Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange.
From an analyst’s perspective:
Previously, Goldman upgraded its rating to Buy on March 08, 2021, and elevated its price target to $6.50. On December 14, 2020, upgrade upgraded it’s rating to Buy but maintained its price target of $5.50 on the stock. Barclays upgraded its rating to a Overweight and increased its price target to $6 on December 14, 2020. Goldman initiated its recommendation with a Sell and recommended $4 as its price target on July 27, 2020. Guggenheim upgraded its rating to Neutral for this stock on May 12, 2020. In a note dated December 12, 2019, Raymond James downgraded an Mkt Perform rating on this stock.
Amneal Pharmaceuticals Inc [AMRX] stock has fluctuated between $1.31 and $6.46 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Amneal Pharmaceuticals Inc [NASDAQ: AMRX] shares were valued at $6.02 at the most recent close of the market. An investor can expect a potential drop of -0.33% based on the average AMRX price forecast.
Analyzing the AMRX fundamentals
Amneal Pharmaceuticals Inc [NASDAQ:AMRX] reported sales of 2.39B for the trailing twelve months, which represents a growth of 1.18%. Gross Profit Margin for this corporation currently stands at 0.34% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at -0.02%, and Net Profit Margin reading is -0.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.76 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 139.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.75 points at the first support level, and at 5.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.20, and for the 2nd resistance point, it is at 6.39.
Amneal Pharmaceuticals Inc [AMRX] reported earnings per share of $0.14 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.09/share, meaning a difference of $0.05 and a surprise factor of 55.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.19 per share as compared to estimates of $0.13 per share, a difference of $0.06 representing a surprise of 46.20%.
Ratios To Look Out For
For context, Amneal Pharmaceuticals Inc’s Current Ratio is 1.63. On the other hand, the Quick Ratio is 0.94, and the Cash Ratio is 0.11. Considering the valuation of this stock, the price to sales ratio is 0.78, the price to book ratio is 93.30.
Transactions by insiders
Recent insider trading involved BOYER ANDREW S, Executive Vice President, that happened on Aug 11 ’23 when 29302.0 shares were sold.
